CENTER FOR EARLY DIAGNOSIS AND THERAPY RESEARCH ON
NEURODEGENERATIVE DISEASES
– A SWEDISH NETWORK
ANNUAL REPORT JULY 2011 – JUNE 2012
Table of Content
Page
Summary ……………………………………………………………..3
Background & Objectives .…………………………………………..4
Outcome & Major Achievements ...………………………………...5
External Collaboration ………………………………………………9
Organisation and infrastructure ....………………………………..11
List of Core Coordinators and other members ...………………..13
Information Dissemination ...……………………………………...16
Research Budget Allocation ...…………………………………....18
Swedish Brain Power in Future …………………………………..20
List of Research Projects ………………………………………….21
Publication List ….…………………………………………...……..24
2
Summary
The Swedish Brain Power (SBP) program started in summer 2005. From July 2010 Knut &
Alice Wallenberg (KAW) Foundation is the sole sponsor (until June 2015). SBP is now well
established as a leading national research network focusing on “early diagnosis and therapy
research on neurodegenerative diseases”. The program also serves as a model for research
networks established in Germany, France and The Netherlands.
Collaboration
One of the main goals for SBP was to increase the interaction between the national experts
in the area and by that increase the possibility to reach the aim of the program. This goal has
definitely been reached; the Swedish Brain Power program has obtained a genuine
understanding, collaboration and interaction between the involved research groups, as well
as individual researchers.
SBP has also led to the establishment of both a Nordic collaborative academic program, and
joint experimental research projects between SBP academia and other national &
international research groups. SBP researchers also has an extensive collaboration with both
pharma and biotech industry, and the involved clinical centers are the first choice
(worldwide) for new, innovative clinical trials.
The SBP initiated quality registry (SveDem) is now established. SveDem currently comprises
30.000 patients (out of which 9.000 from Primary Care) and is the data source for several
quality indicators in dementia care. A large number of research projects and publications are
now based on this registry.
Through SBP joint bio banks all over Sweden, including material from patients with
Alzheimer Disease (AD), Parkinson Disease (PD), Amyotrophic Lateral Sclerosis (ALS) and
healthy controls (cerebrospinal fluid (CSF), fibroblasts, blood, brains, DNA) has been
established. SBP also collaborates with the StratNeuro strategic research program including
Karolinska Institutet, the Royal Institute of Technology (KTH) and the SBP members from
Umeå University.
Scientific outcome
In the scientific field, it is now ”harvest time”. One proof of our scientific outcome is the
large number of articles of high scientific value produced by the SBP researchers (see
attached Publication List). A summary of the major achievements are listed on pages 7-8.
Several SBP researchers have received prestigious awards for their contribution to the
research field, eg the International Alzheimer Association Lifetime Achievement Award,
given to Prof Kaj Blennow, the Eric K Fernström’s award to Prof Henrik Zetterberg for new
research that increases the possibility for early detection of Alzheimer disease and the “Eric
& Waijlit Forsgrens pris” to Profs Bengt Winblad, Laura Fratiglioni and Kaj Blennow.
3
The Swedish Brain Power Program –
Background & Objectives
The Swedish Brain Power (SBP) program was established in July 2005, thanks to the initiative
from the foundations Invest in Sweden Agency (ISA), KK Foundation, Foundation for
Strategic Research, Vårdal Foundation, Knut & Alice Wallenberg Foundation and VINNOVA.
From July 2010, the SBP program is sponsored by KAW for another 5 years (2010-2015) with
in total 100 million SEK.
The network is formed by the Swedish leading research groups in the field of
neurodegenerative disorders with a main focus on ALS, Alzheimer and Parkinson disease.
Through SBP, in-depth collaboration has been established between groups that rarely or not
at all earlier used to collaborate. The SBP research program spans from basic to clinical,
epidemiological and caring research. The organisation is outlined in order to facilitate and
encourage collaboration between the involved research groups. The prioritization of
developing translational research has also created many contacts and new collaborations
between academic research and industry. It is an incentive for the program to keep the
administrative costs as low as possible, and focus our efforts on research.
The overall aim for the SBP network is to improve early diagnosis, treatment and care of
patients affected by neurodegenerative diseases (Alzheimer and Parkinson disease,
Amyotrophic Lateral Sclerosis). These often age-related diseases are a growing public health
problem worldwide due to increased elderly population. There is a great need for new and
more effective treatments for dementia and other neurodegenerative diseases, and for
increased knowledge on how to give the best possible care.
SPECIFIC OBJECTIVES
 To increase our knowledge regarding the pathogenesis of neurodegenerative diseases
 To validate the basic research target findings in cell and animal models
 To translate our basic research on biomarkers
o to improve diagnostic accuracy
4
o to identify adequate target populations for intervention
 To identify new mutations and risk genes
 To further identify and validate preventive strategies and initiate prevention trials
 To validate different treatment strategies in preclinical phases
 To achieve efficacious treatment of neurodegenerative diseases on a personalized
basis
 To develop
o new instruments for improved measurement of intervention/treatment
effects
o new caring strategies, such as environmental, psychosocial, educational etc
5
Outcome & Major Achievements
So far, the Swedish Brain Power program, besides the large number of publications, have
fulfilled many of the outlined objectives and achieved both short term and long term added
value such as:

Swedish Brain Power has emerged as a nationally leading network in neurodegenerative research

Swedish Brain Power facilitates inter- and intradisciplinary collaborations between
researchers nationally

Swedish Brain Power facilitates and encourages the discussion of new ideas for
research. An increased understanding and knowledge of different disciplines has
emerged from the meetings between researchers representing multiple disciplines;
both in-person meetings, minor/larger group meetings, steering committee meetings
and the very successful annual workshops for all SBP members

Swedish Brain Power increases the possibilities for research through the funding and
the additional matching funds due to the good reputation of Swedish Brain Power

Swedish Brain Power has been instrumental in the establishment of Collaboration
contracts for basic research with national and international Biotech and Pharma
industry

The Swedish Brain Power program has become a model for similar networks in
Germany, France, the Netherlands and UK

The success of Swedish Brain Power has also led to the establishment of
collaboration in the Nordic countries (Denmark, Finland, Iceland, Norway and
Sweden) as well as Latvia in the Nordic network “Nordforsk”, headed by SBP
researchers

Stronger evidence-based conclusions on larger pooled sample sizes

Thanks to the Swedish Brain Power program and the pioneering research on
biomarkers, the project BIOMARKAPD within the JPND-EU program is now headed by
Sweden; Project Coordinator Bengt Winblad, PI Kaj Blennow, Co-PI Henrik Zetterberg,
Financial & Administrative Manager Gunilla Johansson. The project involves 51
centers from 23 countries in Europe. The funding is national, in Sweden VR
contributes with approx 2.4 MSEK over three years.
SCIENTIFIC OUTCOME
During current period, 50 research projects have been run, (all project titles are listed on
pages 21-22). A large number of articles proving the scientific high quality of the SBP
research results have been published in high ranked journals. An updated publication list for
the period 2010-07--201206 can be found on our website (www.swedishbrainpower.se).
6
During this year, 94 articles have been published (full publication list at the end of this
report).
Seven “SBP PhD students” have defended their thesis during current period.
MAJOR ACHIEVEMENTS
 First-choice for most worldwide clinical trials in Alzheimer disease; (active and
passive immunotherapy, gamma-secretase inhibitors, NGF (nerve growth factor)
therapy);
o Active vaccination; CAD106. The first Phase I-study has been performed within
the SBP network, showing satisfactory antibody production and no side
effects.
o NGF; Encapsulated NGF cell therapy to the basal forebrain performed in six
patients, showed improved cognition, increased nicotine binding and
improved EEG-activity in 2/6 patients. Additional four patients have now got
NGF-releasing implants.

Development of joint databases (Clinical: SATS, SveDem, Mild Cognitive Impairment.
Epidemiological: Kungsholmen, SNAC-K, H70.)

Establishment of joint bio banks, includes material from patients with AD, PD, ALS
and healthy controls (CSF, fibroblasts, blood, brains, DNA).

Improved early diagnosis including development of new biomarkers for early
diagnosis of cognitive impairment (CSF (Aß, Tau, Proteomics, 24Shydroxycholesterol), PET Imaging (amyloid load, glucose metabolism), MRI (atrophy
hippocampus and temporal lobe), TRX80; potential target molecule for AD
treatment), further developed Neuropsychological tests;
o Combination of Hippocampal volume, neuropsychological test and CSF markers
predict conversion from MCI to dementia to a very high degree.
o Cognitive testing shows that accelerated decline occurs in closer proximity to
diagnosis in Vascular dementia (VaD) compared to Alzheimer disease.
However, once accelerated decline occurs, rate of deterioration is faster in
VaD than in AD.
o Striatal DA D1 receptor density is related to functional brain activation during
working memory and reduced receptor density contributes to altered
activation patterns and impaired cognitive performance in aging. Training of
working memory leads to increased functional brain activity and to increased
release of DA in striatum.

Identification of risk genes and mutations and clarifications of underlying function;
o In ALS; SOD1 and ITPR2. Homozygous deletion of SMN2 has shown to be a
protective genetic factor for developing ALS in Sweden.
o In Frontotemporal lobe dementia; GRN.
o The APOE risk gene for AD, together with a high carbohydrate diet affects
cognitive functions in young mice.
7
o APOE4 induces impairment of the Thioredoxin 1 (Trx1) systems in neurons.
APOE4 affects both synthesis and degradation of Trx1, which is a vital defense
against Aβ.

Establishment of new transgenic animals of great value for the translation of basic
findings into humans (MitoPark, MemoFlex, Swe mutation Tg2576, Swe APP rat);
o In the MemoFlex mice it has been shown that the Nogo receptor 1 (NGR1) is
important for spatial memory and for drug-induced memories. Inability to
down-regulate NGR1 alters sensitization to amphetamine and long term
memory of amphetamine. This is important for understanding addiction and
general memory mechanisms, not the least the role of emotional weight for
strength of memories formed.

Development of technological assessments/training methods (using Virtual reality,
Functional MRI, PET);
o Long periods of cognitive training in patients with Parkinson disease, that foster
strong performance on the criterion task can induce robust transfer even in
elderly participants.

Establishment of new instrument to measure function in normal elderly, MCI patients
and demented individuals and resource utilization in dementia (ETUQ, SITA, Personcentered care, assessment scale for nursing strain, RUD);
o The ETUQ rating scale displayed sound psychometric properties when used on
adult persons with intellectual disabilities and could separate these subjects
into three distinct groups based on their cognitive function. This further
supports the potential of the ability to use technology being a sensitive
marker of disability when cognitive impairment is present.
8
External Collaboration
NATIONAL & INTERNATIONAL “EXTERNAL” COLLABORATION (ie outside SBP)
Except for the internal collaboration between involved SBP research groups, the individual
SBP researchers have an extensive national and international collaboration, eg;
-
EU projects
o EU Dimi, INMIND
o EURODEP
o BIOMARKAPD
o FTD consortium (GWAS), Early onset dementia consortium & the GENFI group
o CLINIGENE (the NGF study was included)
-
National Academic collaboration
o Malmö Diet and Cancer study
o FAS Epi Life Center, Gothenburg (www.epilife.sahlgrenska.gu.se)
o StratNeuro program at Karolinska Institutet
o Dept of Clinical Neuroscience, Dept of Mol Medicine and Surgery, Karolinska
Institutet
o KTH (Royal Institute of Technology)
o Luleå University
-
International Academic collaboration
o NIA & NIH, Bethesda
o MedCoast (Gothenburg-Oslo MCI study)
o Vas-Cog; LADIS
o ICINET
o McGill Univ Canada, South Carolina Univ US (Prof A-C Granholm), John Hopkins
Univ Baltimore
o Ageing Research Unit, Australian National Univ (collaboration to validate an
evidence-based dementia risk assessment tool)
o Prof Ullman Lindenberger, Berlin, Germany
o The IALSA Consortium (www.ialsa.org)
o Dept of Biomedical Engineering, Univ of Alberta, Edmonton, Canada
o Genetic Epidemiology of Parkinson Disease (GEO-PD)
o Prof Nils-Göran Larsson, Max Planck Institute for Biology of Ageing
o Univ of Bologna, Prof Roberto Rimondini
o Tübingen Univ, Dept of Neurology
o La Trobe Univ, Australia
o Oslo Univ, Norway
o Kobe Univ, Japan
-
Industrial
o GE Healthcare
o Bayer Pharma
o DiaGenic
9
o
o
o
o
o
o
o
o
o
o
o
o
NsGene A/S
Context vision AB
Depona AB
Hoffmann-La Roche
AstraZeneca
Hoehringer-Ingelheim
Amorfix Life Sciences
Gyros AB, Uppsala
BioArctic, Stockholm
Daniel Medical Center & Bucheon Medical Center, South Korea
Ibaraki Medical Association, Osaka, Japan
Janssen-Cilag
In addition, a large number of clinical trials, sponsored by the pharma industry, are
performed at the three involved clinics on the SBP prioritized diseases: ALS, Alzheimer and
Parkinson diseases.
10
Organisation and infrastructure
The Swedish Brain Power is organised to facilitate and encourage efficient interdisciplinary
collaboration within the network, as well as external collaboration. In a legal aspect Swedish
Brain Power is a Center of Excellence within Karolinska Institutet (KI) with collaborators all
over Sweden. The Coordination Center is located at the KI Alzheimer Disease Research
Center (KI-ADRC), Department NVS, Karolinska Institutet. SBP is directed by Prof Bengt
Winblad, together with Maria Eriksdotter as co-Director and Gunilla Johansson as
Coordinator.
The SBP work is structured into three research platforms; Clinic-Epidemiology, Basic and
Caring/Technology platforms (green, blue, lilac in the figure below). Each platform is formed
by several cores; eg pre-clinics & transgenic models, epidemiology, care/caring &
rehabilitation. Ethics is a core of its own but not placed in a specific platform, since it
concerns all research areas. Each core consists of research groups from different university
research units, and is lead by scientific core coordinators, who in turn form the Steering
Committee, (further info next page).
The SBP Organisation Plan
Leadership and coordination
SBP is led by a Governing Board with representatives from governmental authorities, the
founder, industry, county council and academia. The Board takes a global responsibility for
the SBP program, takes the final decision on research activities and allocation of the budget,
and makes the policy decisions. The Board members also act as ambassadors for the
program and strive to attract additional funding and industrial collaboration. The Governing
Board meets at least once per term, and additional times if required.
11
Governing Board
Håkan Eriksson, Chair
Agneta Holmäng, Göteborg
Christer Köhler, Stockholm
Staffan Normark, Stockholm
Olle Stendahl, Linköping
Göran Stiernstedt, Stockholm
Co-opted members of the Governing Board
Kerstin Tham, Head of NVS Dept, KI
Bengt Winblad, Director SBP
Maria Eriksdotter, Co-Director SBP
Gunilla Johansson, Coordinator SBP
Steering Committee
The Steering Committee (SC) consists of all core coordinators (see list next page). The SC
deals with more specific issues, such as scientific activities including a first evaluation of the
research projects to be presented to the Board for decision. The SC meets 1-2 times per
term.
Executive Group
The Executive Group deals with the daily decisions and consists of Director Bengt Winblad,
Co-Director Maria Eriksdotter and Coordinator Gunilla Johansson.
SBP PhD’s and PhD students
During the first five years, 40 SBP-connected PhD students have passed their examination.
Currently, SBP-projects involve 36 post docs and 30 registered PhD students obtaining salary
support from the program. In addition a large number of post docs & senior researchers are
mainly/partly involved in the research projects. All collaborators are listed on page 12-14.
During year 7, seven PhD students have defended their thesis;
- Barbara Caracciolo
- Huei-Hsin Chiang
- Michael Jonsson
- Tobias Karlsson
- Olof Lindberg
- Camilla Malinowsky
- Michael Schöll
12
SWEDISH BRAIN POWER – Core Coordinators and Other Members
Director: Bengt Winblad, Professor
Co-Director: Maria Eriksdotter, Professor
Coordinator: Gunilla Johansson
Communication Manager: Annbritt Ryman
Core
Coordinators
Other Members
Diagnostics and Therapeutic research,
Clinical Trial Center
Karolinska Institutet, Stockholm
Agneta Nordberg, Professor
Karolinska Institutet, Stockholm
Niels Andreasen, MD, PhD
Maria Eriksdotter, Professor, MD
Dag Aarsland, Professor, MD
Vesna Jelic, MD, PhD
Taher Darreh-Shori, PhD
Ahmadul Kadir, PhD
Stephen Carter, PhD
Michael Schöll, PhD
Anna Lilja, PhD stud
Ruiqing Ni, PhD stud
Skåne University Hospital, Malmö
Lennart Minthon, Professor
Skåne University Hospital, Malmö
Elisabeth Londos, Assoc Prof, MD
Katarina Nägga, MD, PhD
Oskar Hansson, MD, PhD
Åsa Wallin, MD, PhD
Erik Stomrud, PhD
Gustav Torisson, PhD stud
Malin Lavesson, RN
Sahlgrenska Academy, Univ of
Gothenburg
Anders Wallin, Professor
Sahlgrenska Academy, Univ of
Gothenburg
Arto Nordlund, PhD
Anne Börjesson-Hansson, MD, PhD
Carl Eckerström, PhD
Michael Jonsson, PhD
Maria Svensson, PhD stud
Eva Bringman, research nurse
Ewa Styrud, research nurse
Uppsala University
Lars Lannfelt, Professor
Uppsala University
Martin Ingelsson, Assoc Prof
Joakim Bergström, PhD
Hedvig Welander, PhD
Lund University
Gunnar Gouras, Professor
Lund University
Patrik Brundin, Professor
Davide Tampellini, PhD
Sonia George, PhD
Géraldine Petit, PhD
Karolinska Institutet,Stockholm
Laura Fratiglioni, Professor
Karolinska Institutet, Stockholm
Miia Kivipelto, Professor
Hui-Xin Wang, PhD
Chengxuan Qiu, PhD
Sara Angleman, PhD
Lina Rosvall, PhD
Barbara Caracciolo, PhD
Epidemiology
13
Neuropsychology
Care Research,
Rehabilitation
Sahlgrenska Academy, Univ of
Gothenburg
Ingmar Skoog, Professor
Sahlgrenska Academy, Univ of
Gothenburg
Pernille Olesen, PhD
Svante Östling, PhD
Karolinska Institutet, Stockholm
Lars Bäckman, Professor
Karolinska Institutet, Stockholm
Stuart MacDonald, PhD
Ove Almkvist, PhD
Erika Jonsson Laukka, PhD
Yvonne Brehmer, PhD
University of Gothenburg
Boo Johansson, Professor
University of Gothenburg
Linda Hassing, Assoc Prof
Valgeir Thorvaldsson, PhD
Anne Ingeborg Berg, PhD
Umeå University
Lars Nyberg, Professor
Umeå University
Anna Neely Stigsdotter, PhD
Daniel Sjölie, PhD stud
Urban Ekman, PhD stud
Umeå University, Umeå
Per-Olof Sandman, Professor
Umeå University
Birgit Rasmussen, RN, PhD
David Edvardsson, RN, PhD
Karin Sjögren, RN, PhD stud
Karolinska Institutet
Louise Nygård, Professor
Karolinska Institutet, Stockholm
Lena Borell, Professor
Camilla Malinowsky, PhD
Eva Lindqvist, PhD
Lund University
Anna-Karin Edberg, Professor
Lund University
Anneli Orrung Wallin, PhD stud
University of Gothenburg
Helle Wijk, Assoc Professor
Hanna Falk, PhD
Primary Care, Health Economics,
Interactive training technology
Karolinska Institutet, Stockholm
Anders Wimo, Professor
Linköping University Hospital
Jan Marcusson, Professor
Karolinska Institutet, Stockholm
Linus Jönsson, MD, PhD
Anders Sköldunger, PhD stud
Britt-Marie Sjölund, PhD stud
Linköping Univ Hospital
Anna Segernäs, PhD stud
Umeå University
Helena Lindgren, PhD
Biomarkers (Imaging, CSF etc)
Sahlgrenska Academy, Univ of
Gothenburg
Kaj Blennow, Professor
Sahlgrenska Academy, Univ of
Gothenburg
Henrik Zetterberg, MD, Professor
Niklas Mattsson, PhD
Maria Bjerke, PhD
14
Karolinska Institutet, Stockholm
Lars-Olof Wahlund, Professor
Lars Farde, Professor
Genetics, Brain Bank
Karolinska Institutet, Stockholm
Agneta Nordberg, Professor
Christer Halldin, Professor
Olof Lindberg, PhD
Karolinska Institutet, Stockholm
Caroline Graff, MD, Professor
Karolinska Institutet, Stockholm
Lars Olson, Professor
Mimmi Westerlund, PhD
Andrea Carmine Belin, PhD
Dagmar Galter, PhD
Lina Rosvall, PhD
Anna Anvret, PhD
Huei-Hsin Chiang, PhD
Caroline Ran, PhD
Sandra Gellhaar, PhD
Sahlgrenska Academy, Univ of
Gothenburg
Hans Nissbrandt, Professor
Sahlgrenska Academy, Univ of
Gothenburg
Elias Eriksson, Professor
Olle Bergman, PhD
Umeå University
Peter M Andersen, Professor
Umeå University
Anna Birve, PhD
Lund University
Patrik Brundin, Professor
Pre-clinical research,
Transgenic models
Karolinska Institutet, Stockholm
Lars Olson, Professor
Angel Cedazo-Minguez,
Assoc Professor
Ingemar Björkhem, Professor
Karolinska Institutet, Stockholm;
M Schultzberg, Professor
Nils-Göran Larsson, Professor
Eirikur Benedikz, Assoc Prof
Helena Karlström, PhD
Andrea Carmine Belin, PhD
Dagmar Galter, PhD
Jaime Ross, PhD stud
Erik Hjorth, PhD
Maria Ankarcrona, Assoc Prof
Lars Tjernberg, Assoc Prof
Erik Sundström, Assoc Prof
Uppsala University
Lars Lannfelt, Professor
Martin Ingelsson, Assoc Prof
Hedvig Welander, PhD
Ethics
Karolinska Institutet, Stockholm
Erik Sundström, Assoc Professor
Maria Eriksdotter, Professor
Karolinska Institutet, Stockholm
Sara Stormoen, PhD stud
Kevin Grimes, PhD
Mette Bergman, PhD stud
15
Information dissemination
Knowledge dissemination and communication, both internal and external, is one of SBP’s
priorities. To this end SBP has, since October 2007, engaged a Communication Manager at
halftime to work close together with the Executive Group.
Externally the aim is to reach relevant target groups such as other scientists, physicians,
clinics, patients, decision makers in society and industry as well as the general public.
Internally the aim is to facilitate and enhance the communication and collaboration within
the network.
Both External and Internal
• The SBP website www.swedishbrainpower.se plays an important role in knowledge
dissemination, both externally and internally. The site presents the SBP and SBPrelated news to external target groups and to the public. This year, the news about a
successful study on a “vaccine” against Alzheimer disease, conducted by several
researchers in the network, became one of the top 5 news on the Internet and
reached hundreds of thousands around the world.
• SBP’s presence on Facebook www.facebook.com/SwedishBrainPower and Twitter
twitter.com/SwedBrainPower has also contributed to a growing interest from the
public and media.
• The update of the website included the launch of an internal channel of
communication to further facilitate and enhance communication and cooperation
between the members of the network.
• Efforts to further increase the website’s accessibility and usability is made
continuously by search optimizing and updating both content and technical
functions.
External
• Publication in scientific journals is the main channel for scientific knowledge
dissemination, both nationally and internationally. News about important
publications in major scientific journals is reported on the website in a popular form
along with links to the articles.
•
The prominent scientists in the SBP network often give lectures and present the SBP
program at scientific conferences as well as public meetings and seminars, both
nationally and internationally. This year, among other things, SBP participated at the
“Almedalsveckan” in July (a traditional and popular meeting place for the public and
politicians to discuss social and political issues). Ten of SBP's top scientists appeared
and spoke about the latest research findings in a well-attended seminar, for which
we were happy. However, as we did not manage to attract politicians or journalists,
the evaluation after the event resulted in that our presence during “Almedalsveckan”
will not be repeated. In September SBP co-hosted a seminar on the annual Alzheimer
Day Sep 21, which was broadcasted by Swedish national television (SVT) on the
Knowledge Channel and has been watched by a large number of people.
16
•
Portable roll ups in both Swedish and English for use at public performances have
been produced together with a folder and a flyer to give a short presentation of the
program.
•
In April, Swedish Brain Power got a debate article published in the Swedish
newspaper Dagens Medicin about the future research policy in Sweden. In the article
30 of SBPs top scientists made a joint statement arguing for collaboration and urgent
necessary societal investments in research to combat the big challenge of dementia.
Internal
• Every year, a very appreciated 2-day workshop is organized where all researchers in
the network meet and exchange experiences, ideas and results. This year’s workshop
focussed on giving PhD students and post docs an opportunity to present new cutting
edge projects. Two international well-reputed researchers also presented their work.
During these workshops, many new collaborations are “born”.
17
Research Budget Allocation
The grant for the SBP program during July 2010 – June 2015 (5 yrs) is in total 100 MSEK.
During year 7 (110701—120630), approx 18 MSEK has been allocated to research projects in
form of 50% salary support. Approx 3.2 MSEK has been used for managerial and
administrative costs, including part-time salary for the director, co-director, coordinator and
communication manager, as well as costs related to the website and meetings/travels for all
researchers involved in the program. See table below.
KOORDINATIONSCENTRUM
Lönekostnader
Löner (Director, Co-Director, Adm coord)
Informatör/kommunikatör
Styrelsearvoden
Biostatistiker
SUM LÖNER
ÖVRIGA KOSTNADER
Lokalhyra
Möten (styrelse, ledningsgrupp, arbetsgrupper)
Resor
Workshop SBP
Rekryteringsannonsering
Dator, datorprogram, webhotell
Kontorsmaterial
Övriga driftskostn
SUM ÖVRIGA KOSTN
100701-110630 110701-120630
ÅR 6
ÅR 7
830 833
1 404 828
76 517
402 724
210 000
300 000
0
0
1 117 350
2 107 552
116 000
37 024
74 779
116 000
18 162
113 354
328 605
24 331
16 114
10 598
17 845
296 691
30 494
6 031
44 659
657 305
SUM LÖNE- och ÖVRIGA KOSTNADER
INDI 19%, 19.07% resp 15,38%
1 414 041
267 120
2 764 857
425 235
SUBTOTAL; kostn tagna vid koord-centrum
1 681 161
3 190 092
FÖRDELADE MEDEL TILL DELTAGANDE SBP-GRUPPER
Fördelade medel inkl 19% INDI 201007—12
Fördelade medel inkl 19,07% INDI 201101—06
Fördelade medel inkl 15,38% INDI 201107-201206
6 559 875
7 367 465
18 136 005
SUBTOTAL; FÖRDELADE MEDEL
13 927 340
18 136 005
TOTALA KOSTNADER
15 608 501
21 326 097
18
Below is summarized the allocation (%) of grants 2010-07—201206 (year 6-7) per university
and per project leader. No of Project Leaders per university: KI 18, Gbg 6, Malmö 1, Umeå 4,
Lund 2, Nordanstig 1, Linköping 1, Uppsala 1.
Budget allocation research projects
SBP 2010-07-01 – 2012-06-30
Uppsala
3%
Nordanstig
3%
Linköping
2%
Nordanstig
16%
Umeå
9%
Malmö/Lund
9%
Karolinska
Institutet
56%
Göteborg
18%
Uppsala
16%
Göteborg
16%
Linköping
8%
Umeå
13%
Per university (%)
Malmö/
Lund
16%
Karolinska
Institutet
15%
Per project leader (%)
19
Swedish Brain Power
In FUTURE
Both nationally and internationally, Swedish Brain Power has become a well-known trademark. The
many recent publications in high impact journals and the high number of excellent PhD examinations
so far, is a proof of the scientific quality. The demand on collaboration for budget allocation has been
a good initial incitement to achieve interaction between the research groups and collaboration
between involved researchers is now has well established. Being a part of Swedish Brain Power is
something all are proud of.
Lately many clinical trials on neurodegenerative disorders have failed. This makes it of utmost
importance to be able to continue the basic research and try to find out more about the mechanisms
behind these diseases. It is necessary not to get caught in “old ideas” but have an open mind and
shift focus of the research projects along the way, in accordance with new research findings. Some of
our new research projects are focussed on these new ideas, eg finding CSF/blood biomarkers for
synaptic dysfunction which could lead to a number of neurodegenerative disorders.
Recently, new criteria for diagnosis of Alzheimer disease including preclinical stages, have been
published. In addition to current assessment, biomarkers (such as CSF Aβ and tau measurement and
imaging methods) are added as support for the diagnosis. Using biomarkers, it is assumed that it will
be possible to diagnose AD even before the clinical symptoms are present. The new criteria will be
validated by the clinics in SBP.
As we are now entering into our third year (out of currently supported five), we have started our
efforts to try to attract continuous funding. Unfortunately, most efforts and announcements are
being directed towards project grants and the specific universities. Finding support for networks and
interuniversity research so far seems hard. Still, we are believers and are convinced we will manage
to persuade funding organisations and governmental authorities that it would be a real waste if we
were not able to continue the successful research program of Swedish Brain Power.
For the Swedish Brain Power Program
Bengt Winblad
Director
Maria Eriksdotter
Co-Director
Gunilla Johansson
Coordinator
20
LIST OF RESEARCH PROJECTS
21
CLINICAL PLATFORM (PI within brackets)
1. Multi-tracer PET studies for understanding of disease processes and development of early
diagnostic biomarkers (A Nordberg)
2. Studies of neuroplasticity and functional neurogenesis in AD (A Nordberg)
3. Imaging of astrocytes, fibrillar amyloid load and cerebral glucose metabolism in Tg mice with
APPswe mutation with µPET technique (A Nordberg)
4. The Normal Material Study 2 (NoMaS 2) (L Minthon)
5. Cognitive impairment in elderly medical inpatients (L Minthon)
6. Neurochemical identification of incipient subcortical VaD and AD (A Wallin)
7. Functional and structural brain imaging (MRI) in normal aging, vascular and non-vascular MCI (A
Wallin)
8. Encapsulated cell bio-delivery of nerve growth factor (NGF) to Alzheimer disease patients (M
Eriksdotter)
9. Genetic background and lifestyle-related factors in relation to risk of dementia and cognitive
decline (L Fratiglioni & I Skoog)
10. Pre-mild cognitive impairment, MCI and pre-dementia: identifying different forms of cognitive
decline in large population-based studies in Sweden (L Fratiglioni)
11. Brain atrophy and cerebrovascular disease on CT in elderly population samples; risk factors,
secondary changes and prognosis (I Skoog & LO Wahlund)
12. Individual differences in pre-clinical onset of dementia: What contributes to early/late onset of
accelerated cognitive decline? (L Bäckman & B Johansson)
13. The role of dopamine in cognitive plasticity across the adult life span (L Bäckman)
14. Cognitive training and transfer in normal and pathological aging (L Nyberg)
15. Virtual reality and rehabilitation (L Nyberg)
16. Biomarkers to study molecular mechanisms and disease pathogenesis in AD (K Blennow)
17. Acute effect on the Aβ isoform pattern in CSF in response to treatment in AD patients (K
Blennow)
18. The aging frontal lobe in health and disease (LO Wahlund)
BASIC PLATFORM
19. Genetic, neuropathological and clinical studies in FTLD (C Graff)
20. Clinical and experimental studies of FAD: a model for identifying prognostic and early diagnostic
markers of sporadic AD (C Graff)
21. Coordinator for a common neuropathological strategy in SBP projects (C Graff)
22. Prion-like propagation of Aβ- and tau-pathology in AD: translational studies in Tg mouse models
(P Brundin)
23. Disease-causing mutations in familial PD (H Nissbrandt)
24. Identification and modelling genetic in PD (A Carmine Belin)
25. Closing some of the gaps between genetic studies and pathology (D Galter)
26. Investigating the selective neuronal vulnerability in AD pathogenesis (A Sandebring)
27. Biomarker characterization (CSF and Imaging) of patients with mutations in different genes
associated with ALS and ALS-dementia (P Andersen)
28. Animal models for the formation of lasting memories and to alter plaque load (L Olson)
29. The mitochondria theory of aging, mtDNA mutator mice and high brain lactate as early
biomarker of AD (L Olson)
22
30. Translating ageing findings in mice to human brains. Expression patterns of LDH-A and –B and
other genes found to underlie increased lactate levels in ageing mice (L Olson)
31. APOE genotype and life-style risk factors in AD; to understand the underlying mechanisms (A
Cedazo Minguez)
32. Modulation of gamma-secretase by APOE, a mechanistic explanation leading to sporadic AD (A
Cedazo Minguez)
33. Role of cholesterol metabolism and functions of oxysterols in healthy and AD brains (A Cedazo
Minguez & I Björkhem)
34. Oxysterols in plasma and CSF and possible risk factors for neurodegeneration (I Björkhem)
35. Role of the oxysterol 27-hydroxycholesterol in neurodegeneration (I Björkhem)
36. Inflammation as target for treatment of AD with special focus on the resolution phase (M
Schultzberg)
37. Biomarkers and memory in the transgenic AD rat (E Benedikz)
38. Role of the Aph-1 isoforms in the γ-secretase complex for selective processes of APP and Notch
(H Karlström)
39. Neuronal cell cultures derived from induced pluripotent cells as a platform to study AD
mechanisms (E Sundström)
40. Evaluation of Aß oligomers/protofibrils as biomarkers for Alzheimer disease (L Lannfelt)
CARING / TECHNOLOGY PLATFORM
41. Providing tailored ICT-support to individuals with suspected or early dementia in their home and
to their health professionals (Helena Lindgren)
42. Exploring person-centred care and associated resident and staff outcomes in Swedish residential
aged care units (PO Sandman)
43. Detection of subtle and early signs of disability in terms of difficulties in everyday technology use
in MCI and AD patients (L Nygård)
44. The academic nursing home – a large scale intervention of the national guidelines for care of
dementia (L Borell)
45. Evidence-based environments, optimizing the preconditions for in-patient dementia assessment
(AK Edberg)
46. Functional capacity and costs of care (A Wimo)
47. Dementia; costs for disease, drugs and diagnostics (A Wimo)
48. Cognitive testing and functional evaluation in primary care dementia investigations (J
Marcusson)
49. To live with risk for Alzheimer disease (Maria Eriksdotter)
50. Medical decision making capacity in patients with compromised cognitive functions (E
Sundström)
23
PUBLICATIONS
YEAR 7
24
CLINICAL PLATFORM;
(DIAGNOSTICS, THERAPEUTICS, CLINICAL TRIALS, EPIDEMIOLOGY, NEUROPSYCHOLOGY)
2012
Andersson M, Guo X, Börjesson-Hanson A, Liebetrau M, Östling S, Skoog I. A population
based study on dementia and stroke in 97-year-olds. Age Ageing. 2012 Jul;41(4):529-33.
Andel R, Crowe M, Hahn EA, Mortimer JA, Pedersen NL, Fratiglioni L, Johansson B, Gatz M.
Work-related stress may increase the risk of vascular dementia. J Am Geriatr Soc.
2112;60(1):60-67.
Bao et al. Different amyloid oligomer assemblies in Alzheimer brains correlate with age of
diease onset and impaired cholinergic activity. Neurobiol Aging 2012;33.
Brehmer Y, Westerberg H & Bäckman L. Working-memory training in younger and older
adults: Training gains, transfer, and maintenance. Frontiers in Human Neuroscience,
2012;(6):63.
Caracciolo B, Gatz M, Xu W, Pedersen N, Fratiglioni L. Differential Distribution of Subjective
and Objective Cognitive Impairment in the Population: A Nation-Wide Twin-Study. J
Alzheimers Dis. 2012;29(2):393-403.
Carter S et al. Evidence for astrocytosis in prodromal Alzheimer’s disease provided by 11CDeuterium-L-Deprenyl - A multi-tracer PET paradigm combining 11C-PIB and 18F-FDG. J Nucl
Med, 2012;53:37-46.
Ekman, U, Eriksson J, Forsgren L, Mo S J, Riklund K, & Nyberg L. Functional brain activity and
presynaptic dopamine uptake in patients with Parkinson’s disease and mild cognitive
impairment: a cross-sectional study. Lancet Neurology, 2012;11(8):679–687.
Eriksdotter-Jönhagen M, Linderoth B, Lindb G, Aladellie L, Almkvist O, Andreasen N,
Blennow K, Bogdanovic N, Jelic V, Kadir A, Nordberg A, Sundström E, Wahlund LO, Wall A,
Wiberg M, Winblad B, Seiger Å, Almqvist P, Wahlberg. Encapsulated cell biodelivery of NGF
to the basal forebrain in patients with Alzheimer´s disease. Dem Ger Cogn Disord.
2012;33:18-28.
Eriksdotter-Jönhagen M, Linderoth B, Lind G , Eyjolfsdottir H, Seiger Å, Almqvist P, Wahlberg
L. Intracerebral tillförsel av tillväxtfaktorn NGF med inkapslade celler hos patienter med
Alzheimers sjukdom. Neurologi 1: 25-30, 2012.
Gustafson DR, Bäckman K, Joas E, Waern M, Östling S, Guo X, Skoog I. A 37-years of body
mass index and dementia. Observations from the Prospective Population Study of Women in
Gothenburg, Sweden. J Alzheimers Dis 2012 Jan;28(1):163-71.
Gustafson D, Bäckman K, Lissner L, Carlsson L, Waern M, Östling S, Guo X, Bengtsson C,
Skoog I. Leptin and dementia over 32 years - the Prospective Population Study of Women.
Alzheimer’s & Dement. 2012 Jul;8(4):272-7.
25
Hansson O, Stomrud E, Vanmechelen E, Östling S, Gustafson D, Zetterberg H, Blennow K,
Skoog I. Evaluation of plasma Aβ as predictor of Alzheimer’s disease in older individuals
without dementia: a population-based study. J Alzheimers Dis. 2012 Jan;28(1):231-8.
Hjelm C, Dahl A, Broström A, Mårtensson J, Johansson B, Strömberg A. The influence of heart
failure on longitudinal changes in cognition among individuals 80 years of age and older. J
Clin Nurs. 2012;21(7-8):994-1003.
Joas E, Bäckman K, Gustafson D , Östling S, Waern M, Guo X, Skoog I. Trajectories of blood
pressure from mid- to late-life in relation to dementia in women followed for 37 years.
Hypertension 2012 Apr;59(4):796-801.
Johansson L Skoog I, Gustafson D, Olesen PJ, Waern Bengtsson C, Björkelund C, Pantoni L,
Simoni M, Lissner L, Guo X, Midlife psychological distress associated with late-life brain
atrophy and white matter lesions: a 32-year population study of women. Psychosom Med.
2012 Feb-Mar;74(2):120-5.
Jokinen H, Lipsanen J, Schmidt R, Fazekas F, Gouw AA, van der Flier WM, Barkhof F,
Madureira S, Verdelho A, Ferro JM, Wallin A, Pantoni L, Inzitari D, Erkinjuntti T; LADIS Study
Group. Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS
study. Neurology 2012 May 29;78(22):1785-92.
Landgren S, von Otter M, Seibt Palmér M, Zetterström C, Nilsson S, Skoog I, Gustafson DR,
Minthon L, Wallin A, Andreasen N, Bogdanovic N, Marcusson J, Blennow K, Zetterberg H,
Kettunen P. A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's
disease. J Neural Transm. 2012 Jul;119(7):833-42.
Laukka EJ, MacDonald SWS, Fratiglioni L, Bäckman L Preclinical cognitive trajectories differ
for Alzheimer's disease and vascular dementia. JINS 2012;18:1-9.
Lindberg O, Walterfang M, Looi JCL, Malykhin N, Ostberg P, Zandbelt BB, Oberg J, Zhang Y,
Wahlund L-O. Hippocampal shape analysis in Alzheimer´s disease and frontotemporal lobar
degeneration subtypes. J Alzheimers Dis. 2012 Jan 1;30(2):355-65.
MacDonald S W S, Karlsson S, Rieckmann A & Bäckman L. Age-related increases in behavioral
variability: Relations to losses of dopamine D1 receptors. Journal of Neuroscience, 2012;32:
8186-8191.
Nordberg A et al. European multi-center PET study of fibrillar amyloid in Alzheimer´s
disease. Eur J Nucl Med Mol Imaging DOI 10.1007/s00259-012-2237-2.
Nyberg L, Lövdén M, Riklund K, Lindenberger U & Bäckman L. Memory aging and brain
maintenance. Trends in Cognitive Sciences, 2012;16:292-305.
Qiu C, Zhang Y, Bronge L, Herlitz A, Aspelin P, Bäckman L, Fratiglioni L, Wahlund LO. Medial
temporal lobe is vulnerable to vascular risk factors in men: a population-based study. Eur J
Neurol 2012 Jan 17.
26
Religa D, Spångberg K, Wimo A, Edlund A-K, Winblad B, Eriksdotter-Jönhagen M. Dementia
diagnosis differs in men and women and depends on age and dementia severity. Data from
SveDem, the Swedish Dementia Quality Registry. Ger Cogn Disord 2012;33:90-95.
Schöll M et al. Low PIB PET retention in presence of pathological CSF biomarkers in Arctic
APP mutation carriers. Neurology 2012;79:229-236.
Skoog I, Olesen PJ, Blennow K, Palmertz B, Johnson SC, Bigler ED. Head size may modify the
impact of white matter lesions on dementia . Neurobiol Aging. 2012 Jul;33(7):1186-93.
Thorvaldsson V, Skoog I, Hofer SM, Börjesson-Hansson A, Östling S, Sacuiu S, Johansson B.
Non-linear blood pressure effects on cognition in old age: Separating between-person and
within-person associations. Psychol Aging. 2012 Jun;27(2):375-83.
Wang H-X, Gustafson DR, Kivipelto M, Pedersen NL, Skoog I, Windblad B, Fratiglioni L.
Education halves the risk of dementia due to apolipoprotein epsilon 4 allele: A collaborative
study from the Swedish Brain Power initiative. Neurobiol Aging. 2012 May;33(5):1007.e1-7.
2011
Andel R, Crowe M, Hahn EA, Mortimer JA, Pedersen NL, Fratiglioni L, Johansson B, Gatz M.
Work-related stress may increase the risk of vascular dementia. J Am Geriatr Soc 2012
Jan;60(1):60-7.
Bellander M, Brehmer Y, Westerberg H, Karlsson S, Fürth D, Bergman O, Eriksson E &
Bäckman L. Preliminary evidence that allelic variation in the LMX1A gene influences trainingrelated working memory improvement. Neuropsychologia, 2012;49:1938-1942.
Brehmer Y, Rieckmann A, Bellander M, Westerberg H, Fischer H & Bäckman L. Neural
correlates of training-related working-memory gains in old age. Neuroimage, 2012;58:11101120.
Brodaty H, Breteler, DeKosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg PA, Scheltens
P, De Strooper B. The World of Dementia Beyond 2020. J Am Ger Soc 2011; 59(5): 923-927.
Bäckman L, Karlsson S, Fischer H, Karlsson P, Brehmer Y, Rieckmann A, MacDonald S W S,
Farde L & Nyberg L. Dopamine D1 receptors and age differences in brain activation during
working memory. Neurobiology of Aging, 2011;32:1849-1856.
Bäckman L, Nyberg L, Soveri A, Johansson J, Andersson M, Dahlin E, Neely A S, Virta J, Laine
M & Rinne J O. Effects of working-memory training on striatal dopamine release. Science,
20111;333:718.
Edman A, Edenbrandt L, Fredén-Lindqvist J, Nilsson M, Wallin A. Asymmetric cerebral blood
flow in patients with mild cognitive impairment: possible relationship to further cognitive
deterioration. Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):228-36.
27
Fratiglioni L, Qiu C. Prevention of cognitive decline in ageing: dementia as the target, delayed
onset as the goal. Lancet Neurol. 2011; 10(9): 778-9.
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M,
Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L,
Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A,
Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, SalvadorCarulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, den Bergh PV, van Os
J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; CDBE2010Study Group. Cost of disorders
of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79.
Haasum Y, Fastbom J, Fratiglioni L, Kåreholt I, Johnell K. Pain treatment in elderly persons
with and without dementia: a population-based study of institutionalized and home-dwelling
elderly. Drugs Aging 2011 Apr 1;28(4):283-93.
Karlsson S, Rieckmann A, Karlsson P, Farde L, Nyberg L & Bäckman L. Relationship of
dopamine D1 receptor binding in striatal and extrastriatal regions to cognitive functioning in
healthy humans. Neuroimage, 2011:57:346-351.
Lilja A et al. Functional interaction of fibrillar and oligomeric amyloid-ß with alpha7 nicotinic
receptors in Alzheimer´s disease. J Alzheimer Disease 2011; 23: 335-347.
Lindwall M, Larsman P & Hagger M S. The Reciprocal Relationship Between Physical Activity
and Depression in Older European Adults: A Prospective Cross-Lagged Panel Design Using
SHARE Data. Health Psychology, 2011;30:453-462.
MacDonald S W S, Karlsson S, Fratiglioni L & Bäckman L. Trajectories of cognitive decline
following dementia onset: What accounts for variation in progression? Dementia and
Geriatric Cognitive Disorders, 2011;31:202-209.
Mustafiz T et al. Characterization of the brain ß-amyloid isoform pattern at different ages of
Tg 2576 mice. Neurodegener Dis 2011;8:352-63.
Piccinin AM, Muniz G, Matthews FE, Johansson B. Terminal decline from within- and
between-person perspectives, accounting for incident dementia. J Gerontol B Psychol Sci Soc
Sci. 2011;66(4):391-401.
Rieckmann A, Karlsson S, Fischer H & Bäckman L. Caudate dopamine D1 receptor density is
associated with individual differences in fronto-parietal connectivity during working
memory. Journal of Neuroscience, 2011;31:14284-14290.
Rieckmann A, Karlsson S, Karlsson P, Brehmer Y, Fischer H, Farde L, Nyberg L & Bäckman L.
Dopamine D1 receptor associations within and between dopaminergic parhways in younger
and elderly adults: Links to cognitive performance. Cerebral Cortex, 2011;21:2023-2032.
Rolstad S, Berg AI, Bjerke M, Blennow K, Johansson B, Zetterberg H, Wallin A. Amyloid-β₄₂ is
associated with cognitive impairment in healthy elderly and subjective cognitive impairment.
J Alzheimer’s Dis. 2011;26(1):135-42.
28
Schöll M et al. Time course of glucose metabolism in relation to cognitive performance and
postmortem neuropathology in Met146ValPSEN1 mutation carriers. J Alzheimer’s Dis
2011;24:495-506.
The LADIS Study Group, Poggesi A, Pantoni L, Inzitari D, Fazekas F, Ferro J, O'Brien J,
Hennerici M, Scheltens P, Erkinjuntti T, Visser M, Langhorne P, Chabriat H, Waldemar G,
Wallin A, Wahlund A. 2001-2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study:
What Have We Learned about White Matter Changes and Small-Vessel Disease? Cerebrovasc
Dis. 2011;32(6):577-588.
29
BASIC RESEARCH PLATFORM
(EXPERIMENTAL RESEARCH, GENETICS, ANIMAL MODELS)
2012
Anvret A, Ran C, Westerlund M, Gellhaar S, Lindqvist E, Pernold K, Lundströmer K, Duester G,
Felder MR, Olson L, Galter D and Belin AC. Adh1 and Adh1/4 knockout mice as possible
rodent models for presymptomatic Parkinson's disease. Behavioral Brain Research. 2012 Feb
1;227(1):252-7.
Anvret A, Ran C, Westerlund M, Galter D, Sydow O, Willows T, Olson L, Belin AC. Genetic
Screening of Mitochondrial Rho GTPases, MIRO1 and MIRO2, in Parkinson’s disease. Open
Neurol J. 2012;6:1-5.
Belin AC, Ran C, Anvret A, Paddock S, Westerlund M, Håkansson A, Nissbrandt H, Söderkvist
P, Dizdar N, Ahmadi A, Anvret M, Willows T, Sydow O, Galter D. Association of a protective
paraoxonase 1 (PON1) polymorphism in Parkinson's disease. Neurosci Lett. 2012 Jul
26;522(1):30-5.
Corcia P, Ingre C, Blasco H, Press R, Praline J, Antar C, Veyrat C, Guettard YO, Camu W,
Andersen PM, Andres C, Vourc’h P. Homozygous SMN2 deletion is a protective factor in the
Swedish ALS population. Eur J Hum Genet 2012;20:588-91.
Daher JP, Pletnikova O, Biskup S, Musso A, Gellhaar S, Galter D, Troncoso JC, Lee MK,
Dawson TM, Dawson VL, Moore DJ. Neurodegenerative phenotypes in an A53T α-synuclein
transgenic mouse model are independent of LRRK2. Hum Mol Genet. 2012 Jun
1;21(11):2420-31.
Diekstra FP, van Vught PWJ, van Rheenen W, Koppers M, Pasterkamp RJ, van Es MA,
Schelhaas HJ, de Visser M, Robberecht W, Andersen PM, van den Berg LH, Veldink JH.
UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging 2012;33.
Diekstra FP, Saris CGJ, van Rheenen W, Franke L, Jansen RC, van Es MA, van Vught PWJ,
Blauw HM, Groen EJN, Horvath S, Karol Estrada K, Rivadeneira F, Hofman A, Uitterlinden AG,
Robberecht W, Andersen PM, Melki J, Meininger V, Hardiman O, Landers JE, Brown, Jr. RH,
Shatunov A, Shaw CE, Leigh PN, Al-Chalabi A, Ophoff RA, van den Berg LH, Veldink JH.
Mapping of Gene Expression Reveals CYP27A1 as a Susceptibility Gene for Sporadic ALS. PloS
ONE 2012;7:e35333.
Gil-Bea F, Akterin S, Persson T, Mateos L, Sandebring A, Avila-Cariño J, Gutierrez-Rodriguez
A, Sundström E, Holmgren A, Winblad B, Cedazo-Minguez A.Thioredoxin-80 is a product of
alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in
Alzheimer's disease brain. EMBO Mol Med. 2012 Oct;4(10):1097-111.
Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I; Geisen C, Gitler AD, Becker T, Weber M, Berg
D, Andersen PM, Krüger R, Riess O, Ludolph AC, Auburger G. The modulation of Amyotrophic
30
Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect.
Neurobiol Dis 2012;45:356-361.
Hedskog L, Brohede J, Wiehager B, Pinho CM, Revathikumar P, Lilius L, Glaser E, Graff C,
Karlström H, Ankarcrona M. Biochemical Studies of Poly-T Variants in the Alzheimer's
Disease Associated TOMM40 Gene. J Alzheimers Dis. 2012 May 16.
Hjorth E, Freund-Levi Y. Immunomodulation of microglia by docosahexaenoic acid and
eicosapentaenoic acid. Curr Opin Clin Nutr Metab Care 2012;15:134-143.
Ibáñez C, Simó C, Martín-Álvarez PJ, Kivipelto M, Winblad B, Cedazo-Mínguez A, Cifuentes A.
Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass
spectrometry metabolomics. Anal Chem. 2012 Oct 16;84(20):8532-40.
Kacem I, Funalot B, Torny F, Lautrette G, Andersen PM, Couratier P. Early-onset
parkinsonism associated with an intronic SOD1 mutation. ALS 2012;13:315-317.
Katz JS, Katzberg HD, Woolley SC, Marklund SL, Andersen PM. Fronto-temporal dementia
with Aphasia and later Amyotrophic Lateral Sclerosis in a Patient with the I113T SOD1 Gene
Mutation. ALS 2012;13:567-9.
Maioli S, Puerta E, Merino-Serrais P, Fusari L, Gil-Bea F, Rimondini R, Cedazo-Minguez A.
Combination of apolipoprotein e4 and high carbohydrate diet reduces hippocampal BDNF and arc
levels and impairs memory in young mice. J Alzheimers Dis. 2012 Jan 1;32(2):341-55.
Miralbell J, Spulber G, Hooshmand B, Besga A, Mataró M, Cedazo-Minguez A, Kivipelto M,
Wahlund LO. Grey matter and cognitive patterns in cognitive impaired subjects using CSF
biomarker cut-offs. J Alzheimers Dis. 2012;29(4):741-9.
Ran C, Westerlund M, Anvret A, Willows T, Sydow O, Galter D, Belin AC. Genetic studies of
the protein kinase AKT1 in Parkinson's disease. Neurosci Lett. 2011 Aug 21;501(1):41-4.
Sarlus H, Olgart Höglund C, Karshikoff B, Wang X, Lekander M, Schultzberg M, Oprica M.
Allergy influences the inflammatory status of the brain and enhances tau phosphorylation. J
Cell Mol Med 2012 Feb 22.
Smith BN, Newhouse S, Vance C, Lee Y, Weale ME, Topp S, Millar J, Johnson L, Troakes C,
Hortobagyi T, Al-Sarraj S, Rogelj B, Powell J, Lupton M, Lovestone S, Sapp P, Nestor PS,
Schelhaas, Silani V, Gelera C, Van den Berg L, Veldink J, van Damme P, Robberecht W, de
Jong V, Shaw PJ, Kirby J, Paul H, Morrison KE, Bass, Andersen PM, Landers J, Brown RH, AlChalabi A, Shaw CE. The C9ORF72 expansion mutation is derived from a single founder in
European ALS/FTD patients and is highly unstable. Eur J Hum Genet, Epub June 13, 2012.
Synofzik M, Rochi D, Keskin I, Basak AN, Wilhelm C, Gobbi C, Birve A, Biskup S, Zecca C,
Fernandez-Santiago R, Kaugesaar T, Schöls L, Marklund SL, Andersen PM. Mutant Superoxide
Dismutase-1 Indistinguishable from Wild Type Causes ALS. Hum Mol Genet 2012;21:35683574.
31
Wanngren J, Ottervald J, Parpal S, Portelius E, Strömberg K, Borgegård T, Klintenberg R,
Juréus A, Blomqvist J, Blennow K, Zetterberg H, Lundkvist J, Rosqvist S, Karlström H. Second
generation γ-secretase modulators exhibit different modulation of Notch β and Aβ
production. J Biol Chem. 2012 Jul 31.
Wuolikainen A, Moritz T, Marklund SL, Andersen PM, Antti H. ALS patients with mutations in
the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with
ALS patients without mutations. Mol Genet Metabol 2012;105:472-8.
2011
Carew JD, Nair G, Gronka S, Hu X, Andersen PM, Benatar M. Presymptomatic spinal cord
neurometabolomic findings in SOD1+ people at risk of familial ALS. Neurology 2011;77:13701375.
Couthis J, Hart MP, Shorter J, Dejesus-Hernandez M, Erion R, Oristano R, Liu AX, Ramos D,
Jethava N, Hosangadi D, Epstein J, Chiang A, Diaz Z, Nakaya T, Ibrahim F, Kim HJ, Solski JA,
Williams KL, Mojsilovic-Petrovic J, Ingre C, Boylan K, Graff-Radford NR, Dickson DW, ClayFalcone D, Elman L, McCluskey L, Greene R, Kalb RG, Lee VM, Trojanowski JQ, Ludolph A,
Robberecht W, Andersen PM, Nicholson GA, Blair IP, King OD, Bonini NM, Van Deerlin V,
Rademakers R, Mourelatos Z, Gitler AD. Feature article: A yeast functional screen predicts
new candidate ALS disease genes. Proc Natl Acad Sci U S A 2011;108:20881-20890.
Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, de Carvalho M, Meyer T, Tysnes O-B,
Auburger G, Gispert S, Andersen PM, Gitler AD. Ataxin-2 intermediate-length polyglutamine
expansions in European ALS patients. Hum Mol Genet 2011;9:1697-1700.
Pamrén A, Wanngren J, Tjernberg LO, Winblad B, Bhat R, Näslund J, Karlström H. Mutations
in nicastrin protein differentially affect amyloid beta-peptide production a Notch protein
processing. J Biol Chem. 2011 Sep 9;286(36):31153-8.
Ross JM. Visualization of mitochondrial respiratory function using cytochrome c oxidase /
succinate dehydrogenase (COX/SDH) double-labeling histochemistry. Journal of Visualized
Experiments (57), e3266, DOI: 10.3791/3266 (2011). PMID:22143245
Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S,
Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E,
Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R,
Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger
R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C,
Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L,
Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EMvan de Loo S, Vassilatis DK, Vilariño-Güell
C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ; Genetic Epidemiology Of
Parkinson's Disease (GEO-PD) Consortium*. Association of LRRK2 exonic variants with
susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011
Oct;10(10):898-908. * Global Site Principal investigator of GEO-PD in Sweden.
32
Spulber S, Bartfai T, Winblad B, Schultzberg M. Morphological and behavioural changes
induced by transgenic overexpression of IL-1ra in the brain. J Neurosci Res 2011;89:142-52.
van Es MA, Schelhaas HJ, van Vught PWJ, Ticozzi N Andersen PM, Groen EJN, Schulte C,
Blauw HM, Koppers M, Diekstra FP, Fumoto K, LeClerc AL, Keagle P, Bloem BR, Scheffer H,
van Nuenen BFL, van Blitterswijk M, van Rheenen W, Wills A-M, Lowe PP, Hu G, Yu W,
Kishikawa H, Wu D, Folkerth RD, Mariani C, Goldwurm S, Pezolli G,van Damme P, Lemmens
R, Ingre C, Birve A, Fernández-Santiago R, Waibel S, Klein C, Weber M, van der Kooi AJ, de
Visser M, Verbaan D, van Hilten BJ, Heutink P, Hennekam EAM, Cuppen E, Berg D, Brown Jr
RH, Silani V, Gasser T, Ludolph AC, Robberecht W, Ophoff RA, Veldink JH, Pasterkamp RJ, de
Bakker PIW, Landers JE, van de Warrenburg BP, van den Berg LH. Angiogenin variants in
Parkinson’s Disease and amyotrophic lateral sclerosis. Ann Neurol 2011;70:964-973.
Weber M, Neuwirth C, Schweikert K, Czaplinski A, Jung HH, Birve A, Marklund SL, Andersen
PM. ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and
extreme long survival. J Neurol Neurosurg Psychiatry 2011.
33
CARE/CARING PLATFORM
(CARE, REHABILITATION, TECHNOLOGY, PRIMARY CARE, HEALTH ECONOMY)
2012
Bergland, Å, Kirkevold M, Edvardsson D. Psychometric properties of the Norwegian Personcentered Climate Questionnaire from a nursing home context. Scand J Caring Sciences.
DOI: 10.1111/j.1471-6712.2012.00979.
Edvardsson D, Sandman PO & Rasmussen B. Forecasting the ward climate: A study from a
dementia care unit. J Clin Nursing 2012 21, 1136-1144.
Lindholm C, Gustavsson A, Jönsson L, Wimo A. Costs explained by function rather than
diagnosis—results from the SNAC Nordanstig elderly cohort in Sweden. Int J Geriatr
Psychiatry. 2012;jul 11.
Nygård L, Pantzar M, Uppgard B & Kottorp A. Detection of disability in older adults with MCI
or Alzheimer’s disease through assessment of perceived difficulty in using everyday
technology. Aging and Mental Health, 2012;16(3-4):361-371.
Pellfolk T, Lövheim H, Sandman PO, Gustafsson Y, Karlsson S. Physical restraint use in
geriatric care in Sweden between 2000 and 2007. Int Psychogeriatr 2012; 24:7,1144–1152.
Rokstad AMM, Engedal K, Edvardsson D, Selbæk G. Validity and reliability of the Norwegian
version of the Person-centred Care Assessment Tool (P-CAT). Int J of Nursing Practice 2012;
18, 99-105.
Sjögren K, Sandman PO, Zingmark K, Edvardsson D. Psychometric evaluation of the Swedish
version Person-centred Care Assessment Tool (P-CAT). Int Psychoger 2012 24, 406-415.
Sköldunger A, Wimo A, Johnell K. Net costs of dementia in Sweden - An Incidence Based 10
Year Simulation Study. Int J Geriatr Psychiatry. 2012 Feb 1.
Wimo A, Gaudig M, Schäuble B, Jedenius E. The economic impact of galantamine vs placebo:
An analysis based on functional capacity in a Swedish cohort study. J Med Econ. 2012 Apr 23.
2011
Brorsson A, Öhman A, Lundberg S & Nygård L. Accessibility in public space as perceived by
people with Alzheimer’s disease. Dementia, 2011;10(4):587-602.
Edvardsson D, Fetherstonhaugh D, McAuliffe L, Chenco C & Nay R. Job satisfaction amongst
aged care staff – exploring the influence of person-centred care provision. Int Psychoger
2011; 23, 1205-1212.
34
Edvardsson D, Fetherstonhaugh D & Nay R. The Tool for Understanding Residents’ Needs as
Individual Persons (TURNIP): construction and initial testing. J Clin Nursing 2011;20, 28902896.
Hällgren M, Nygård L & Kottorp A. Technology and everyday functioning in people with
intellectual disabilities: A Rasch analysis of the Everyday Technology Use Questionnaire
(ETUQ). J Intellectual Disability Research, 2011;55(6):610-620.
Lövheim H, Gustafson Y, Karlsson S, Sandman PO. Comparison of behavioral and
psychological symptoms of dementia and psychotropic drug treatments among old people in
geriatric care in 2000 and 2007. Int Psychoger 2011; 23:10,1616–1622
35